Narcolepsy can lead to excessive daytime sleepiness, as well as cataplexy, a sudden loss of muscle tone. Other symptoms can include sleep paralysis and hallucinations that occur both during sleep ...

Alkermes plc ALKS announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2). The ...

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton ...

People with certain types of long-term sleep disorders may use a medicine called sodium oxybate to help treat their condition. This medicine is taken at night and may help people with narcolepsy to ...

ZURICH, SWITZERLAND / ACCESSWIRE / January 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the ...

Recognizing markers like atonia index during wakefulness (WAI) that are not present in other hypersomnias might help in the diagnosis of narcolepsy. Atonia index during wakefulness (WAI) might ...

If you or someone in your household has narcolepsy, you know how much this condition can affect daily life. People with narcolepsy have fragmented nighttime sleep and extreme sleepiness during the day ...

– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the ...